Viridian Therapeutics, Inc. (VRDN) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Viridian Therapeutics, Inc. (VRDN) Bundle
Whether you’re an investor or analyst, this (VRDN) DCF Calculator is your go-to resource for accurate valuation. Featuring real data from Viridian Therapeutics, Inc., you can adjust forecasts and observe the effects in real-time.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.5 | 1.1 | 3.0 | 1.8 | .3 | .2 | .2 | .1 | .1 | .1 |
| Revenue Growth, % | 0 | -76.46 | 182.19 | -40.2 | -82.28 | -24.73 | -24.73 | -24.73 | -24.73 | -24.73 |
| EBITDA | -40.8 | -109.7 | -78.8 | -128.6 | -234.6 | -.2 | -.2 | -.1 | -.1 | -.1 |
| EBITDA, % | -913.47 | -10444.57 | -2659.13 | -7259.2 | -74702.23 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .3 | .5 | .6 | .8 | .5 | .1 | .1 | .1 | .0 | .0 |
| Depreciation, % | 6.46 | 51.33 | 20.92 | 42.61 | 166.24 | 44.26 | 44.26 | 44.26 | 44.26 | 44.26 |
| EBIT | -41.0 | -110.2 | -79.4 | -129.4 | -235.1 | -.2 | -.2 | -.1 | -.1 | -.1 |
| EBIT, % | -919.93 | -10495.9 | -2680.05 | -7301.81 | -74868.47 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 26.8 | 127.6 | 197.0 | 424.6 | 477.4 | .2 | .2 | .1 | .1 | .1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .2 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | .0 | .5 | .1 | .1 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 2.42 | 0 | 15.22 | 5.76 | 32.48 | 11.18 | 11.18 | 11.18 | 11.18 | 11.18 |
| Inventories | .0 | .0 | .0 | -6.6 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | -373.76 | 0 | -20 | -20 | -20 | -20 | -20 |
| Accounts Payable | 1.1 | .7 | 2.3 | 14.2 | 2.2 | .2 | .1 | .1 | .1 | .1 |
| Accounts Payable, % | 24.57 | 63.81 | 78.6 | 803.27 | 713.06 | 73.4 | 73.4 | 73.4 | 73.4 | 73.4 |
| Capital Expenditure | -.1 | .0 | -.3 | -.8 | -.9 | -.1 | -.1 | .0 | .0 | .0 |
| Capital Expenditure, % | -1.88 | -4 | -11.41 | -44.98 | -285.99 | -32.45 | -32.45 | -32.45 | -32.45 | -32.45 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -41.6 | -110.5 | -79.4 | -125.0 | -235.1 | -.2 | -.2 | -.1 | -.1 | -.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -40.4 | -110.3 | -77.9 | -106.1 | -254.1 | -2.1 | -.2 | -.2 | -.1 | -.1 |
| WACC, % | 9.69 | 9.69 | 9.69 | 9.68 | 9.69 | 9.68 | 9.68 | 9.68 | 9.68 | 9.68 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -1 | |||||||||
| Present Terminal Value | -1 | |||||||||
| Enterprise Value | -3 | |||||||||
| Net Debt | -82 | |||||||||
| Equity Value | 79 | |||||||||
| Diluted Shares Outstanding, MM | 45 | |||||||||
| Equity Value Per Share | 1.76 |
What You Will Get
- Editable Forecast Inputs: Adjust key assumptions (growth %, margins, WACC) effortlessly to explore various scenarios.
- Real-World Data: Viridian Therapeutics, Inc. (VRDN) financial data pre-loaded to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model that tailors to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Comprehensive DCF Calculator: Provides detailed unlevered and levered DCF valuation models tailored for Viridian Therapeutics, Inc. (VRDN).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with options for customizable inputs.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to Viridian Therapeutics, Inc. (VRDN).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- Download the Template: Get instant access to the Excel-based VRDN DCF Calculator.
- Input Your Assumptions: Adjust yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically updates Viridian Therapeutics’ intrinsic value.
- Test Scenarios: Simulate different assumptions to evaluate potential valuation changes.
- Analyze and Decide: Use the results to guide your investment or financial analysis.
Why Choose This Calculator for Viridian Therapeutics, Inc. (VRDN)?
- Designed for Experts: A sophisticated tool utilized by biopharma analysts, investors, and financial advisors.
- Comprehensive Data: Viridian's historical and projected financials are preloaded for reliable analysis.
- Flexible Scenario Analysis: Easily test various forecasts and assumptions to evaluate potential outcomes.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance ensures a smooth and efficient experience.
Who Should Use This Product?
- Investors: Accurately assess Viridian Therapeutics’ fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis related to Viridian Therapeutics (VRDN).
- Consultants: Easily customize the template for valuation reports tailored to clients interested in Viridian Therapeutics (VRDN).
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech companies.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies in the biotechnology sector.
What the Template Contains
- Pre-Filled Data: Includes Viridian Therapeutics' historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for determining WACC based on customized inputs.
- Key Financial Ratios: Assess Viridian Therapeutics' profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.